platelet rich plasma is being used in infertility management extensively without sound evidence of its value. In this talk, we will discuss the real impact of using PRP in IVF
Platelet-rich plasma (PRP) has become popular as a non operative treatment option for a broad spectrum of medical disorders. There are reasonable amount of data which warrant continued research in PRP but currently its role in clinical practice is not completely defined. Prior to its use, special consent is required after an honest and open discussion with the patient as well controlled human studies are lacking
platelet rich plasma is being used in infertility management extensively without sound evidence of its value. In this talk, we will discuss the real impact of using PRP in IVF
Platelet-rich plasma (PRP) has become popular as a non operative treatment option for a broad spectrum of medical disorders. There are reasonable amount of data which warrant continued research in PRP but currently its role in clinical practice is not completely defined. Prior to its use, special consent is required after an honest and open discussion with the patient as well controlled human studies are lacking
NEW USES OF LASER IN GYNECOLOGY
International Society for the Study of Vulvovaginal Disease (ISSVD)
International Continence Society (ICS)
2019 Guidelines
Since the first formal description of LPD in 1949 as a possible cause of infertility and recurrent miscarriage by Jones. Innumerable investigations have been undertaken in an effort to verify its existence or to characterize its pathophysiology, diagnosis, and treatment. The consensus of the literature is that LPD does exist and that its cause is multifactorial like abnormal folliculogenesis, inadequate LH surge,inadequate secretion of progesterone by the corpus luteum, aberrant end-organ response by the endometrium.
Invited Lecture delivered by Dr Sujoy Dasgupta in the Annual Conference of ISAR (Indian Society of Assisted Reproduction) held at Kolkata in November, 2019
there is a change in attitude for monofollicular ovulation induction to treat infertility: previously clomiphene citrate was the standard drug to start with : Now it is different
Platelet Rich Plasma ( PRP ) is very popular in the treatment of musculo skeletal pathologies. This ppt gives a brief introduction to platelets and in sights into developing a PRP kit.
NEW USES OF LASER IN GYNECOLOGY
International Society for the Study of Vulvovaginal Disease (ISSVD)
International Continence Society (ICS)
2019 Guidelines
Since the first formal description of LPD in 1949 as a possible cause of infertility and recurrent miscarriage by Jones. Innumerable investigations have been undertaken in an effort to verify its existence or to characterize its pathophysiology, diagnosis, and treatment. The consensus of the literature is that LPD does exist and that its cause is multifactorial like abnormal folliculogenesis, inadequate LH surge,inadequate secretion of progesterone by the corpus luteum, aberrant end-organ response by the endometrium.
Invited Lecture delivered by Dr Sujoy Dasgupta in the Annual Conference of ISAR (Indian Society of Assisted Reproduction) held at Kolkata in November, 2019
there is a change in attitude for monofollicular ovulation induction to treat infertility: previously clomiphene citrate was the standard drug to start with : Now it is different
Platelet Rich Plasma ( PRP ) is very popular in the treatment of musculo skeletal pathologies. This ppt gives a brief introduction to platelets and in sights into developing a PRP kit.
VCare Trichology hair care clinic in Chennai and Bangalore offers world class hair growth treatments and hair transplantation therapies with a team of expert hair doctors, Trichologists and surgeons at a state of art facility clinic
Dr. David Greene R3 Stem Cell Injections Platelet-Rich Plasma.pptxR3 Stem Cell
Regenerative medicine therapies use the body's natural healing agents to promote tissue regeneration and repair, such as bones and joints. Dr David Greene uses this type of regenerative medicine with his r3 stem cell injection, PRP therapy, and platelet-rich plasma therapy. If you’re looking for a doctor who can help you promote healing through advanced regenerative medicine therapies, call today!
Haven’t been able to witness the joy of becoming a mother even after all the strenuous attempts? Lost all hopes due to recurrent unsuccessful IVF and Implantation? Or have seen the face of failure or cancellation every time you’re prepared for Transfers due to unready endometrium? Have all these failed attempts made you wondered why? No it’s nothing close to a curse, just a medical uncertainty that can be looked after.
PRP ( Platelet Rich Plasma ) is a Autologous blood which contains platelets higher than normal.
Normal platelet count is 4.5 × 105/μL, but PRP has 4–5 times the normal value.
Platelet Rich Fibrin (PRF) in Dentistry, What is PRF ? , What are the difference between PRP,PRGF and PRF ?, Preparation of PRF , shapes of PRF, Role of PRF in wound healing, APPLICATIONS OF PRF, Applications of PRF In Oral and Maxillofacial Surgery, Applications of PRF In Periodontics, Applications of PRF In Endodontics, Applications of PRF In Tissue Engineering
Intra caesarean loop (device or system ) insertion
contraception
side effect advantages gynecology obestetrics infertility egypt dumiat ras el bar city
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
2. Introduction
• Regenerative biomedicine continues to progressively
emerge at the forefront of healthcare in a number of
medical disciplines
• Platelet-rich plasma (PRP) is becoming more popular as
a nonoperative treatment option for a broad spectrum
of medical disorders.
• PRP is widely used in orthopedic and sports medicine to
relieve pain through the natural promotion of healing in
musculoskeletal diseases such as tendonitis, arthritis,
ligament sprains, and tears.
• These growth factors have been found to promote
natural healing responses by researchers across
multiple specialties, such as dentistry, dermatology,
urology, and gynecology
3. What is Platelet Rich Plasma (PRP)?
• It’s a autologous ( means patient’s own blood)
concentration of platelets in a small volume of
plasma usually 5 to 10 fold the normal level of
the whole blood.
• Since the platelets is so concentrated, so do all
the growth factors also will be 5 to 10 folds
higher.
4. FDA approval
• PRP does not require FDA approval
• Since
• It is not a medicine or a device.
• PRP comes from patient own body.
• Patient own blood is drawn and sterilely
processed in a highly specialized FDA
approved collection kit and centrifuge to
concentrate the platelets 6 times their natural
values in pure plasma without any red cells.
5. Short history
• 1905 : German surgeon August Bier discovered that, injected with their own blood, patients with bone
fractures heal faster.
• 1935 – 1980:before antibiotics, autohemotherapy (intramuscular injection of a small amount of blood
taken from the same individual) and autoserotherapy (treatment with blood from the patient’s blood) were
among the most popular secondary treatments.
• 1980 : maxillofacial surgeon Robert E. Marx was the first to use blood plasma as a gel; the discovery that
platelets contain protein factors (PRP factors) that stimulate cellular regeneration opened the way for the
autologous plasma gel production technology; this was developed mainly for use in stomatology (the
Harvest company, USA).
• 2003 : the Russian scientists Renat R. Akhmerov (Professor, Doctor of Medicine, plastic surgeon and
maxillofacial surgeon, oncodermatologist) and Roman F. Zarudy (Doctor of Medicine, maxillofacial surgeon,
implantologist) were the first in the world to use platelet-rich autologous plasma to treat inflammatory and
atrophic diseases, in the postoperative period; the technology was named Plasmolifting™.
• 2004 : Plasmolifting ™ clinical trials were carried out on the two Russian scientists and on volunteers, to
treat photodermatosis, hair loss and acne, with good results (in addition to the therapeutic effects, the
patients’ skin was rejuvenated); Roman F. Zarudy explained that the new injecting form of plasma opened
up new possibilities for them, as maxillofacial surgeons (especially for tissue regeneration), and the method
revolutionized this sphere of surgical practice; at first, their colleagues were skeptical of his new
technology’s success, but – with time – the Plasmolifting™ method began to be applied in various fields of
medicine.
• 2011 : with the support of doctors Akhmerov and Zarudy, the Plasmolifting Company was set up; it
exclusively produces and distributes the equipment necessary for the Plasmolifting™ method, wishing to
offer everyone this natural healing method; today, the Plasmolifting Company has created a vast
distribution network in Europe, develops and distributes the Plasmolifting™ tubes and organizes specialty
courses; the aim of the company is to convert autologous plasma injections into a routine biological
stimulation method.
6. PRP composition and activation
• Platelets contain high concentrations of cytokines and growth
factors stored within α-granules. These growth factors include
platelet-derived growth factor, insulin-like growth factor, vascular
endothelial growth factor, platelet-derived angiogenic factor,
transforming growth factor beta, fibroblast growth factor,
epidermal growth factor, connective tissue growth factor, and
interleukin-8. In addition to growth factors, platelets contain other
substances, such as fibronectin, vitronectin, and sphingosine 1-
phosphate, that initiate wound healing
• Platelet activation triggers the release of these growth factors by a
variety of substances or stimuli such as thrombin, calcium
chloride, and collagen. Each method influences both the physical
form of PRP and the amount of growth factors released, as well as
the kinetics of release. No evidence has been found regarding the
ideal concentration of activator required to trigger the optimal
release of growth factors during the activation process of PRP, and
different concentrations may therefore lead to different results
7. The theory underlying this treatment
modality
• It was derived from natural healing processes,
as the body's first response to tissue injury is to
deliver platelets to the injured area.
• Platelets promote healing and attract stem cells
to the site of the injury.
• Moving from basic science to clinical practice,
• PRP injections have been applied to diseased
ligaments, tendons, and joints, with superb
outcomes in terms of repair
8. Growth Factors In Platelets
• Platelets is part of the cell in our blood that help in the clotting
mechanisms. It’s a very tiny cells but inside the contain a lot of
important growth factors such as:-
• Platelet Derived Growth Factors (PDGF)
• Vascular Endothelial Growth Factors (VEGF)
• Insulin Like Growth Factors ( IGF 1& 2)
• Transforming Growth Factors beta( TGF-b)
• Fibroblast Growth Factors ( FGF)
• Epidermal Growth Factors ( EGF )
• Connective Tissue Growth Factors (CTGF)
• Interleukin 8 (IL 8)
• All these growth factors are very important for healing,
formation of new vessels, collagen production and regeneration!
9. The science of PRP
• PRP preparation
• The preparation of PRP is an outpatient procedure that involves a blood draw, preparation of the PRP,
and the injection of PRP into the diseased area.
• Multiple methods have been developed for PRP preparation, with variation in the speed and timing of
centrifugation
• The following steps present a representative method of preparing PRP:
• (1) venous blood (15–50 mL) is drawn from the patient's arm in anticoagulant-containing tubes;
• (2) the recommended temperature during processing is 21℃–24℃ to prevent platelet activation during
centrifugation of the blood;
• (3) the blood is centrifuged at 1,200 rpm for 12 minutes;
• (4) the blood separates into three layers: an upper layer that contains platelets and white blood cells, an
intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains
red blood cells;
• (5) the upper and intermediate buffy layers are transferred to an empty sterile tube. The plasma is
centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and
platelets) at the bottom of the tube;
• (6) the upper two-thirds of the plasma is discarded because it is platelet-poor plasma;
• (7) pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP;
• (8) the PRP is now ready for injection. Approximately 30 mL of venous blood yields 3–5 mL of PRP;
• (9) the affected area is disinfected before the PRP injection;
• (10) providing assurance to the patient and discussing the procedure make the injection easier and less
painful;
• (11) PRP stimulates a series of biological responses, and the injection site may become swollen and
painful for roughly 3 days.
11. Improving Tone Of Labia Majora And
Labia Minora
• The Vampire Wing Lift is a simple in-office
procedure literally rejuvenate the labia (wings )
and “lift” them back to the natural shape of
each individual woman’s younger self.
• This painless procedure injects patient own
platelet blood plasma into the labia majora (
and minora) to rejuvenate & stimulate it to
address the issues of labial atrophy
• all patients received three PRP treatments
spread four to six weeks apart, then a final
treatment at 12 months
12. Vaginal rejuvenation
(‘Vampire’ vagina injections)
• Aesthetic practitioners have used PRP for the
regeneration of vaginal mucosa, muscles, and skin.
• After PRP injection, vaginal vascularity is increased,
with a subsequent dramatic increase in sensitivity. In
addition, the skin becomes thicker and firmer,
making the vagina look much more youthful.
Moreover, the ligaments and muscles supporting the
urethra become stronger, alleviating urinary
incontinence
• Application of autologous lipofilling mixed with PRP
in a patient with vaginal atrophy produced relief of
symptoms and contour restoration.
13. PRP In Reconstructive Surgery For
Vulvar Cancer
• The efficacy of platelet gel application in
women after radical surgery.
• Platelet gel placed on the vaginal breach during
reconstructive surgery,
• Significantly lower rates of wound infection
,necrosis of vaginal wounds ,and wound
breakdown
• A reduction in the postoperative fever rate, a
shorter hospital stay, and faster wound healing
14. How long does the entire process take?
• The injection takes less than 5 minutes,
• but an hour is scheduled to provide ample
time for patient
• to meet with the doctor to ensure that there
are no contraindications, review pre and post
procedure expectations, draw blood,
centrifuge the blood and prepare the
treatment in a relaxed, comfortable
environment.
15. What prep is given for local
anesthesia?
• After counseling, patient will empty her bladder and
• move to the treatment table where patient will undress
from the waist down, and cover with a sheet.
• doctors find that an extra injection of local pain control
often hurts more than the shot itself.
• Therefore, doctors use 20 – 30 minutes of a topical
numbing cream (Benzocaine, Lidocaine, Tetracaine).
• This is applied to the clitoral and vaginal areas, with a piece
of plastic wrap placed over the cream by the patient and the
medical assistant just before the blood draw.
• Patient MUST tell doctor BEFOREHAND if patient have any
allergic reactions to any of these medications, so doctors
can make arrangements.
16. Contraindications to PRP Therapy
• Acute infectious diseases.
• Viral hepatitis B and C.
• Systemic diseases.
• Allergic reactions to anticoagulants.
• Immunosuppressive conditions.
• Blood-clotting disorder.
• Pregnancy and lactation.
• Mental disorders.
• With a personal history of oncology.
• Age under 18 years.
17. Are there side effects?
• Be assured the treatment rarely has side effects.
• Even patients that have drug allergies can safely
opt for the procedure and enjoy significant
improvement within a few weeks following the
treatment.
• Occasionally there is a small amount of bruising
or tingling in the injected areas.
• There are no infections or cancers or other
adverse side effects known.
18. Recommended course of PRP Therapy
• A course of 1 to 4 procedures is recommended,
• depending on the intensity of changes,
• the time between injections being 1 month.
• doctors recommend 1 treatment to start and see
how patient response is.
• Your provider may recommend more depending
on a multitude of patient-specific factors.
• Re-evaluate after 12-18 months
19. What if it doesn't work?
• A majority of women experience definite improvement
in their symptoms.
• If patient have followed every instruction properly,
• doctors will review a full assessment of the potential
reasons for the sub-optimal results.
• The main issue is usually not the preparation or
performance of the injection, but a woman’s own
particular body’s ability to heal, using its own blood
components, and her following the pre and post
procedure instructions precisely.
• doctors will consider performing a second injection only
after 6 months of healing and a full assessment.
20. Benefits of PRP Therapy
• The PRP Therapy uses patient’s own blood, therefore, this method
has the minimum number of contraindications, and the risk of
allergy, rejection and other “side effects” is completely excluded,
which ensures complete biocompatibility of the administered
preparation.
• The PRP Therapy does not require special training and, under
certain conditions, can be performed immediately at the doctor’s
office. The whole procedure takes no more than 30 minutes. After
the autoplasma injection, the patient can continue her daily routine
at once.
• The PRP Therapy is designed to create a “favorable background” for
the successful treatment of many gynecological diseases.
• The PRP Therapy reduces the drug load (the need to take a lot of
medicines) on the body and minimizes the risk of recurring
pathology.
21. Recommendations after PRP Therapy
• For 3 days after the administration, it is
recommended to abstain from:
Sexual activity.
Taking steam baths.
Visiting saunas and taking baths.
• Use cotton underwear for 5 days after the PRP
Therapy.
• In order to avoid hyperpigmentation at the
injection site, it is not recommended to use a
tanning bed/booth and undergo prolonged
exposure to direct sunlight (tanning) for 1 week.
22. The success of this technique
• entirely depends on
• the speed of blood collection and transfer to the
centrifuge.
• In fact, without anticoagulant, the blood sample
starts to coagulate almost immediately upon
contact with the tube glass, and it does take a
minium of few minutes of centrifugation to
concentrate fibrinogen in the middle and upper
part of the tube.
• Quick handling is the only way to obtain a
clinically usable PRF clot.
23. Conclusion
• PRP is an innovative therapeutic modality,
• as it is affordable,
• simple,
• cheap,
• easily performed, and
• effective.
• It is also a noninvasive modality with promising results and
• no side effects.
• In the field of gynecology, the few studies that have been
conducted are pilot studies, case series, and case reports.
• The risks of PRP therapy as infection, bleeding, and nerve
damage, appear to be minimal.
• Large randomized controlled studies are required to
confirm its efficacy and safety in various gynecological
disorders.